Answers are grounded in this paper and cite their sources.
Nogo-A is well known as an inhibitor of neurite outgrowth. Accumulating evidence suggests that it may also participate in the pathogenesis of non-small cell lung cancer (NSCLC), an aggressive malignancy with a 5-year survival rate of only 16.6%. However, the role of Nogo-A in NSCLC remains poorly understood, partly due to the potential cross-reactivity of antibodies targeting different Nogo isoforms, which may lead to ambiguous results. Here, we employed bioinformatics analyses to identify candidate binding proteins of Nogo-A, followed by coimmunoprecipitation (Co-IP) for experimental validation. A 2-step protein–protein docking procedure combined with molecular dynamics (MD) simulations was subsequently performed to explore the possible binding mechanisms between Nogo-A and CERT1. In addition, a protein–protein interaction network was constructed to explore the possible functional role of Nogo-A in NSCLC. The results revealed that Nogo-A expression was elevated in NSCLC tissues compared with normal tissues. CERT1, SNX15, and SYT16 were identified as candidate Nogo-A-binding proteins, among which CERT1 was experimentally confirmed to bind with Nogo-A in H1299 NSCLC cells overexpressing Nogo-A. MD simulations further suggested that Nogo-A might bind to CERT1 via its reticulon homology domain (RHD), with the interaction involving both the PH and START domains of CERT1. Network enrichment analysis indicated that Nogo-A might be involved in apoptotic processes through the modulation of CERT1-mediated ceramide binding and transport. Taken together, our findings identify CERT1 as a novel putative interacting partner of Nogo-A in NSCLC. The predicted binding interface and its potential functional association with apoptosis provide a basis for future mechanistic studies.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: